

- Evaluation of allogeneic haploidentical NK cells transfusion in patients with acute myeloid leukemia (Non-M3) transplanted with allogeneic hematopoietic stem cells (Clinical trial phase I)
- Preliminary evaluation of the infusion of allogenic NK cells given by apparently healthy voluntary donors treated with IL15 and IL2 in non-m3 acute myeloid leukemia (non-m3 AML) patients (Clinical Trials phase I & II)
- Safety of in-vitro expanded human natural killer cells in high-risk multiple myeloma (HRMM) patients (Clinical trial phase I)